Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Galida – Dual PPAR

Drug (brand/generic)

Galida (tesaglitazar) is a dual-acting oral peroxisome proliferator-activated receptor (PPAR) agonist

Company/licensee

AstraZeneca

Therapy class

Dual-acting PPAR agonist

Product description

Oral peroxisome proliferator-activated receptor which targets both PPAR-alpha and PPAr-gamma

Current indication

Treatment of type 2 diabetes/metabolic syndrome

Market sector

Diabetes

Development status

Discontinued
Expand
Close
Close
Close

Go Top